CINCINNATI , April 30, 2019 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the second quarter and first six months ended March 31, 2019 . Second Quarter 2019 Highlights: Total revenue decreased 11% to $50.2 million , as compared to $56.5 million

CINCINNATI , April 30, 2019 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced it has entered into a definitive agreement to acquire the business of GenePOC Inc.

CINCINNATI , April 18, 2019 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced the launch of its Inhibitor-tolerant qPCR Mix, a novel mix to accelerate workflows and improve DNA target amplification and quantification from crude samples; adding to its growing portfolio of

CINCINNATI , April 10, 2019 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials will report second quarter 2019 financial results Tuesday, April 30, 2019 . Jack Kenny , Chief Executive Officer, and Eric Rasmussen ,

CINCINNATI , April 02, 2019 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today provided a business update including preliminary sales results for its second fiscal quarter and revised financial guidance for

CINCINNATI , Feb. 07, 2019 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced that following the successful release of the Lyo-Ready qPCR Mix, Meridian is proud to introduce its next-generation lyophilization-ready mixes for one-step RT-qPCR.

CINCINNATI , Jan. 24, 2019 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the first quarter ended December 31, 2018 . First Quarter 2019 Highlights: Total revenue decreased 1.5% to $51.5 million , as compared to $52.3 million in the first quarter

CINCINNATI , Jan. 07, 2019 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, announced that it expects first quarter 2019 revenue to be approximately $51.0 million to $51.5 million compared to $52.3 million in